UBX - Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution | Benzinga
Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and raised the price target from $2 to $4.
Unity Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. Unity's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases.
Following the positive 12 week, 18 week, 24 week and 48 week results from the Ph2 BEHOLD trial for UBX1325/DME, the company is set to initiate a head-to-head Ph2b trial for UBX1325 against aflibercept in patients with DME later ...